June 2012, Vol 1, No 2

Dual Targeting in Advanced Melanoma Encouraging

Hitting 2 targets may be better than 1 in advanced melanoma, suggests a preliminary trial of combination therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib. Combined targeting with these 2 agents achieved tumor regression with a lower incidence of skin side effects compared with published data on [ Read More ]

Alice Goodman

Conference Correspondent

Neoadjuvant Abiraterone Potential Approach

Abiraterone, which is FDA-approved for the treatment of advanced prostate cancer, had encouraging results in one of the first studies to evaluate use of this targeted agent earlier in the course of disease. Targeted hormonal therapy with abiraterone plus leuprolide was able to eradicate cancer in the prostate in some [ Read More ]

Phoebe Starr

Conference Correspondent

ALK-Targeted Agent Has High Activity in Some Childhood Cancers

In a preliminary phase 1 study, the targeted drug crizotinib (Xalkori) stabilized disease progression and, in some children, eradicated cancer cells in relapsed, refractory, aggressive childhood cancers that are likely to harbor genetic abnormalities in the ALK gene: anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumors (IMT), and aggressive neuroblastoma. [ Read More ]

Alice Goodman

Conference Correspondent

Personalizing Therapeutics for Melanoma in the 21st Century

Advocating for biomarker-driven “smart” trials, making the case for patient selection for specific drugs, and the concept of rational combinations as potential targeted therapies in order to improve the efficacy of clinical trials were topics of an insightful presentation delivered by Dr Aleksandar Sekulic on behalf of Dr Pat LoRusso [ Read More ]

Kristin Siyahian

Conference Correspondent

Personalized Medicine Advances in Melanoma: An Interview With K. Peter Hirth, PhD

Plexxikon, a member of the Daiichi Sankyo Group since 2011, works in the structureguided discovery and development of novel small-molecule pharmaceuticals to treat human disease. The company’s lead drug Zelboraf (vemurafenib/PLX4032) was approved by the FDA in August 2011 and is copromoted in the United States by Daiichi Sankyo, Inc. [ Read More ]

K. Peter Hirth, PhD

Ask the Expert

Implementing the Promise of Personalized Cancer Care

To receive credit, complete the posttest at www.mlicme.org/P11077.html.   Until recently, cancer treatment relied solely on histologic diagnosis for determining systemic therapy. Aside from considerations related to a patient’s underlying comorbidities and performance status, there was minimal deviation from an organ-of-origin–based treatment strategy. This relatively primitive understanding of malignancy failed [ Read More ]

RĂ¼diger Hehlmann, MD, PhD

Continuing Education

Rapid Changes in Reimbursement Protocols for Molecular Tests

Molecular tests have proliferated over the past decade, bringing the precision of genomics into reality in the clinic, but the payment system for nucleic acid–based tests has been unchanging and primitive. This unfortunate state of affairs has limited the ability of payers to encourage (or control) the use of genomic [ Read More ]

Bruce Quinn, MD, PhD

Regulatory Issues

Management of Ipilimumab-Related Toxicities

Ipilimumab, a monoclonal antibody that blocks the negative costimulatory molecule CTLA-4 on T cells, leading to augmented T-cell activation and proliferation, improves overall survival (OS) in patients with metastatic melanoma and was approved by the regulatory agencies in the United States and several other countries for the treatment of unresectable [ Read More ]

Patrick A. Ott, MD, PhD

Melanoma

Crizotinib Miracle: A Nursing Perspective

For every nurse there is a patient who you will never forget; the details of that story will not blur over time. In the developing era of personalized medicine, there is that 1 patient whose story I will not easily forget. It is the story of a 24-year-old male medical [ Read More ]

Tara L. Rich, MSN, RN, CNP

Lung Cancer